Morgan Stanley’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-82,569
| Closed | -$426K | – | 6940 |
|
|
2019
Q2 | $426K | Buy |
82,569
+35,977
| +77% | +$162K | ﹤0.01% | 4691 |
|
|
2019
Q1 | $168K | Sell |
46,592
-257,353
| -85% | -$1.12M | ﹤0.01% | 5154 |
|
|
2018
Q4 | $1.86M | Sell |
303,945
-160,926
| -35% | -$982K | ﹤0.01% | 3833 |
|
|
2018
Q3 | $2.71M | Sell |
464,871
-31,462
| -6% | -$157K | ﹤0.01% | 3751 |
|
|
2018
Q2 | $2.11M | Buy |
496,333
+97,847
| +25% | +$493K | ﹤0.01% | 4034 |
|
|
2018
Q1 | $1.76M | Sell |
398,486
-29,660
| -7% | -$132K | ﹤0.01% | 4122 |
|
|
2017
Q4 | $2.25M | Buy |
428,146
+339,502
| +383% | +$2.08M | ﹤0.01% | 3935 |
|
|
2017
Q3 | $543K | Buy |
88,644
+2,054
| +2% | +$13K | ﹤0.01% | 4830 |
|
|
2017
Q2 | $626K | Buy |
86,590
+37,570
| +77% | +$231K | ﹤0.01% | 4659 |
|
|
2017
Q1 | $260K | Sell |
49,020
-58,301
| -54% | -$394K | ﹤0.01% | 5185 |
|
|
2016
Q4 | $771K | Buy |
107,321
+26,079
| +32% | +$211K | ﹤0.01% | 4655 |
|
|
2016
Q3 | $760K | Buy |
81,242
+74,399
| +1,087% | +$618K | ﹤0.01% | 4245 |
|
|
2016
Q2 | $43K | Buy |
6,843
+577
| +9% | +$3.71K | ﹤0.01% | 5574 |
|
|
2016
Q1 | $35K | Buy |
6,266
+3,193
| +104% | +$12K | ﹤0.01% | 5745 |
|
|
2015
Q4 | $17K | Buy |
3,073
+204
| +7% | +$1.35K | ﹤0.01% | 6092 |
|
|
2015
Q3 | $24K | Sell |
2,869
-166,026
| -98% | -$2.81M | ﹤0.01% | 5994 |
|
|
2015
Q2 | $2.55M | Sell |
168,895
-59,038
| -26% | -$852K | ﹤0.01% | 3399 |
|
|
2015
Q1 | $3.65M | Buy |
227,933
+100,008
| +78% | +$1.78M | ﹤0.01% | 3045 |
|
|
2014
Q4 | $2.28M | Buy |
127,925
+109,862
| +608% | +$1.37M | ﹤0.01% | 3462 |
|
|
2014
Q3 | $181K | Buy |
18,063
+9,367
| +108% | +$114K | ﹤0.01% | 5195 |
|
|
2014
Q2 | $136K | Buy |
8,696
+6,277
| +259% | +$88.9K | ﹤0.01% | 5350 |
|
|
2014
Q1 | $45K | Buy |
2,419
+1,931
| +396% | +$38.7K | ﹤0.01% | 5754 |
|
|
2013
Q4 | $9K | Buy |
+488
| New | +$9.91K | ﹤0.01% | 6065 |
|
Other funds holding PETX
Morgan Stanley's PETX Position: Q3 2019 in Review
Morgan Stanley sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 82,569 shares — an estimated $426K sold.
Morgan Stanley first reported a position in PETX in Q4 2013 and held it in 23 quarters. The position peaked at $3.65M in Q1 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Morgan Stanley reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Morgan Stanley sold 82,569 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $426K.
- Morgan Stanley first reported a position in Aratana Therapeutics, Inc. in Q4 2013 and held it in 23 quarters.
- Morgan Stanley's Aratana Therapeutics, Inc. position peaked at $3.65M in Q1 2015.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Morgan Stanley's 13F filing for Q3 2019, filed 14 Nov 2019.